Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-002963
Filing Date
2025-07-10
Accepted
2025-07-10 16:10:22
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 11236
2 JOINT FILING AGREEMENT p25-1510exhibit991.htm EX-99.1 5113
  Complete submission text file 0000902664-25-002963.txt   18232
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-37761 | Film No.: 251116439
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902
Business Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902 203-890-2000
Point72 Asset Management, L.P. (Filed by) CIK: 0001603466 (see all company filings)

EIN.: 465064661 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G